LONDON (Reuters) - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.
Former top Nomura analyst Amit Roy, who now runs independent research firm Foveal, thinks sales of drugs inhibiting Programmed Death receptor (PD-1), or a related target PD-L1, will sell much less than expected.
Also read: Tesla Posts Second Profitable Quarter Ever
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger23
12:23 Lockheed Martin's quarterly profit handily beats estimates20
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents19
16:51 Scottrade Sale Nearly Doubles Owner’s Wealth to $4 Billion13